New fixed dose chemical combinations: the way forward for better diabetes type II management?

Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin

(2015) Ralph A. DeFronzo et al.   DIABETES CARE

Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?

(2015) Richard Simpson et al.   Expert Review of Clinical Pharmacology

AACE Comprehensive Diabetes Management Algorithm 2013

(2015) Alan Garber et al.   Endocrine Practice

Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)

(2014) John B. Buse et al.   DIABETES CARE

Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy

(2014) Ajay Kumar   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

(2014) Stephen C L Gough et al.   Lancet Diabetes & Endocrinology

Erratum to: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

(2013) Clifford J Bailey et al.   BMC Medicine

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

(2013) M. Monami et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Efficacy and safety of Jentadueto® (linagliptin plus metformin)

(2013) André J Scheen   Expert Opinion On Drug Safety

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Oral antidiabetic therapy in a large Italian sample: drug supply and compliance for different therapeutic regimens

(2013) A. Vittorino Gaddi et al.   PUBLIC HEALTH

Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology

(2012) Chrysi Koliaki et al.   ADVANCES IN THERAPY

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes

(2012) R. A. DeFronzo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

(2011) Valerie Hutchins et al.   CURRENT MEDICAL RESEARCH AND OPINION

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

(2011) Roberta Baetta et al.   DRUGS

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors

(2010) Priscilla A. Hollander et al.   POSTGRADUATE MEDICINE

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among texas medicaid recipients

(2008) Chelim Cheong et al.   CLINICAL THERAPEUTICS

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

(2008) M. A. Nauck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Characterization of the Influence of Vildagliptin on Model-Assessed β-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia

(2007) Andrea Mari et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM